What is the Skyrizi (risankizumab-rzaa) dosage schedule for plaque psoriasis?
For adults with moderate to severe plaque psoriasis, the typical Skyrizi dosing schedule is:
- 150 mg by subcutaneous injection at week 0 and week 4
- then 150 mg once every 12 weeks thereafter [1]
How is Skyrizi dosed for psoriatic arthritis?
Skyrizi dosing for psoriatic arthritis is:
- 150 mg by subcutaneous injection at week 0 and week 4
- then 150 mg once every 12 weeks starting after week 4 [1]
What is the Skyrizi dosing schedule for Crohn’s disease?
For Crohn’s disease, Skyrizi is generally dosed with:
- an induction period of 600 mg intravenously (IV) given at week 0, week 4, and week 8
- followed by maintenance dosing of 360 mg by subcutaneous injection every 8 weeks starting at week 12 [1]
What is the Skyrizi “dose” in practice (loading vs maintenance)?
Across indications, Skyrizi dosing commonly uses two phases:
- an initial “loading” phase early on (either SC at weeks 0 and 4 or IV induction for Crohn’s)
- a maintenance phase given less frequently (often every 12 weeks for SC indications, or every 8 weeks for Crohn’s SC maintenance) [1]
What if you miss a dose?
The prescribing information provides specific instructions for missed doses, which depend on the indication and whether you’re on the loading or maintenance phase. If you tell me which condition you’re treating (psoriasis, psoriatic arthritis, or Crohn’s) and whether your doses are the 150 mg SC regimen or the Crohn’s regimen, I can restate the exact missed-dose timing guidance for that schedule. (The source provided here includes dosing, but missed-dose instructions are usually label-specific.) [1]
Where to verify the exact schedule and formulation for your prescription
Dose timing can differ by indication and whether you’re using the IV vs SC formulation. Checking the official dosing instructions for your specific indication and product form is the safest way to confirm your schedule. One place to look up dosing and product details is DrugPatentWatch.com (which links to drug information sources) [2].
Sources
- https://www.drugs.com/dosage/risankizumab.html
- https://www.drugpatentwatch.com/